Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
How Remi Bader's documented Ozempic use and discontinuation rebound compares to other celebrity GLP-1 disclosures, with clinical context on weight regain after stopping semaglutide.
Read clinical reviewA clinical timeline of Remi Bader's confirmed Ozempic use, discontinuation, weight regain, and bariatric surgery, with peer-reviewed context for each phase from the HealthRX.com Medical Team.
Read clinical reviewRemi Bader publicly shared her Ozempic experience, including rapid weight regain after stopping. The HealthRX.com Medical Team examines what clinical data says about GLP-1 discontinuation and long-term maintenance.
Read clinical reviewRemi Bader has openly discussed side effects from Ozempic and the weight regain she experienced after stopping. The HealthRX.com Medical Team maps her public statements to the FDA label and peer-reviewed trial data.
Read clinical reviewPlus-size influencer Remi Bader publicly confirmed using and then stopping Ozempic, with rapid weight regain that mirrors clinical trial data. Here is what that same GLP-1 journey costs a non-celebrity patient navigating insurance, compounding pharmacies, and long-term access.
Read clinical reviewRemi Bader publicly confirmed using and discontinuing Ozempic, experiencing significant weight regain. The HealthRX.com Medical Team breaks down the clinical protocol behind her story and what STEP-1 extension data tells us about GLP-1 discontinuation rebound.
Read clinical review